Clomiphene analogs with activity in vitro and in vivo against human breast cancer cells

Biochemical Pharmacology

Volumn 55, Issue 6, 1998, Pages 841-851

  Baumann, R Jeffrey ^a,d   Bush, Tammy L ^a   Cross Doersen, Doreen E ^a   Cashman, Elizabeth A ^a   Wright, Paul S ^a   Zwolshen, John H ^a   Davis, Gregory F ^a   Matthews, Donald P ^b   Bender, David M ^c   Bitonti, Alan J ^a  

^a SANOFI   (France)

^b ELI LILLY AND COMPANY   (United States)

^c Department of Environmental and Radiological Health Sciences   (United States)

^d Oncology ^*  (United States)

Author keywords

Antiestrogens; Breast cancer; Clomiphene analogs; Estrogen receptor; LY2; MCF 7; Tamoxifen resistance

Indexed keywords

1 BUTANAMINE 4 [4 (2 CHLORO 1,2 DIPHENYETHENYL)PHENOXY] N,N DIETHYL DIHYDROGEN CITRATE; ANTIESTROGEN; CLOMIFENE; ESTRADIOL; ESTROGEN RECEPTOR; MDL 101 986; MDL 103 323; N [4 (2 CHLORO 1,2 DIPHENYLVINYL)PHENYL] N,N DIETHYLETHYLENEDIAMINE DIHYDROGEN CITRATE; TAMOXIFEN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; BREAST CANCER; CANCER CELL CULTURE; DRUG RECEPTOR BINDING; DRUG STRUCTURE; FEMALE; GENE REPRESSION; HORMONE RESPONSIVE ELEMENT; HUMAN; HUMAN CELL; INTRAPERITONEAL DRUG ADMINISTRATION; MOUSE; NUDE MOUSE; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION;

EID: 0032520737     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(97)00574-1     Document Type: Article

References (46)

1. Breast cancer overview. In: An Analysis of Breast Cancer 1987-1990 with Projections for 1992 (Eds. Mortenson LE, Fritz AG, Balanoff H, Clune C and Skloven L), p. 1. Elm Services, Inc., Rockville, 1992.
2. Breast cancer: Estrogen receptor. In: An Analysis of Breast Cancer 1987-1990 with Projections for 1992 (Eds. Mortenson LE, Fritz AG, Balanoff H, Clune C and Skloven L), p. 14. Elm Services, Inc., Rockville, 1992.
3. Thompson EW, Katz D, Shima TB, Wakeling AE, Lippman ME, Dickson RB. ICI 164, 384, a pure antagonist of estrogen-stimulated MCF-7 cell proliferation and invasiveness. Cancer Res. 49:1989;6924-6934.
4. Hecker E, Vegh I, Levy CM, Magin CA, Martinez JC, Loureiro J, Garola RE. Clinical trial of clomiphene in advanced breast cancer. Eur J Cancer. 10:1974;747-749.
5. Stenbygoard LE, Herrstedt J, Thomsen JF, Svendsen KR, Engelholm SA, Dombernowsky P. Toremifene and tamoxifen in advanced breast cancer - A double-blind crossover trial. Breast Cancer Res Treat. 25:1993;57-63.
6. Nayfield SG, Karp SE, Ford LG, Dorr FA, Kramer BS. Potential role of tamoxifen in prevention of breast cancer. J Natl Cancer Inst. 83:1991;1450-1459.
7. Effects of adjavant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women. N Engl J Med. 319:1988;1681-1692.
8. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomized trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet. 339:1992;71-85.
9. Lerner LJ, Holthaus FJ Jr, Thompson CR. A non-steroidal estrogen antagonist 1-(p-2-diethylaminoethoxyphenyl)-1-phenyl-2-p-methoxyphenyl ethanol. Endocrinology. 63:1958;295-318.
10. Segal JS, Nelson WO. An orally active compound with antifertility effects in rats. Proc Soc Exp Biol Med. 98:1958;431-436.
11. Kistner RW, Smith OW. Observations on the use of a non-steroidal estrogen antagonist MER-25 . Surg Forum. 10:1960;725-729.
12. Holtkamp DE, Greslin SC, Root CA, Lerner LJ. Gonadotropin inhibiting and antifecundity effects of chloramiphene. Proc Soc Exp Biol Med. 105:1960;197-201.
13. Duncan GW, Lyster SC, Clark JJ, Lednicer D. Antifertility activities of two diphenyl-dihydronaphthalene derivatives. Proc Soc Exp Biol Med. 112:1963;439-442.
14. Harper MJK, Walpole AL. A new derivative of triphenylethylene effect on implantation and mode of action in rats . J Reprod Fertil. 13:1967;101-119.
15. Jordan VC. Biochemical pharmacology of antiestrogen action. Pharmacol Rev. 36:1984;245-275.
16. Herbst AL, Griffiths CT, Kistner RW. Clomiphene citrate (NSC-36770) in disseminated mammary carcinoma. Cancer Chemother Rep. 43:1964;39-41.
17. Legha SS, Carter SK. Antiestrogens in the treatment of breast cancer. Cancer Treat Rev. 3:1976;205-216.
18. Bronzert O, Greene G, Lippman M. Selection and characterization of a breast cancer cell line resistant to the antiestrogen LY117018. Endocrinology. 117:1985;1409-1417.
19. Rubinstein LV, Shoemaker RH, Paull KD, Simon RM, Tosini S, Skehan P, Scudiero DA, Monks A, Boyd MR. Comparison of in vitro anticancer-drug-screening data generated with a tetrazolium assay versus a protein assay against a diverse panel of human tumor cell lines. J Natl Cancer Inst. 82:1990;1113-1118.
20. Murphy LC, Sutherland RL. Antitumor activity of clomiphene analogs in vitro; relationship to affinity for the estrogen receptor and another high affinity antiestrogen-binding site. J Clin Endocrinol Metab. 57:1983;373-379.
21. Sutherland RL, Baulieu EE. Quantitative estimates of cytoplasmic and nuclear oestrogen receptors in chick oviduct. Effect of oestrogen on receptor concentration and subcellular distribution. Eur J Biochem. 70:1976;531-541.
22. Katzenellenbogen JA, Johnson HJ Jr, Myers HN. Photoaffinity labels for estrogen binding proteins of rat uterus. Biochemistry. 12:1973;4085-4092.
23. Wakeling AE. Anti-hormones and other steroid analogues. Green B, Leake RE. Steroid Hormones A Practical Approach . 1987;219-236 IRL Press, Oxford.
24. Korenman SG. Relation between estrogen inhibitory activity and binding to cytosol of rabbit and human uterus. Endocrinology. 87:1970;1119-1123.
25. Slater EP, Redenilk G, Beato M. Hormonal regulation of vitellogenin genes An estrogen-responsive element in the Xenopus A2 gene and a multihormonal regulatory region in the chicken ll gene . Mol Endocrinol. 5:1991;386-396.
26. McKnight SL, Kingsbury R. Transcriptional control signals of a eukaryotic protein-coding gene. Science. 217:1982;316-324.
27. Bitonti AJ, Dumont JA, Bush TL, Cashman EA, Cross-Doersen DE, Wright PS, Matthews DP, McCarthy JR, Kaplan DA. Regression of breast tumor xenografts in response to (E)-2′-deoxy-2′-(fluromethylene)cytidine, an inhibitor of ribonucleoside diphosphate reductase. Cancer Res. 54:1994;1485-1490.
28. Brünner N, Bronzert D, Vindeløv LL, Rygaard K, Spang-Thomsen M, Lippman ME. Effect on growth and cell cycle kinetics of estradiol and tamoxifen on MCF-7 human breast cancer cells grown in vitro and in nude mice. Cancer Res. 49:1989;1515-1520.
29. Sutherland RL, Watts CKW, Hall RE, Ruenitz PC. Mechanisms of growth inhibition by nonsteroidal antioestrogens in human breast cancer cells. J Steroid Biochem. 27:1987;891-897.
30. Sutherland RL, Murphy LC, Hall RE, Reddel RR, Watts CKW, Taylor IW. Effects of antioestrogens on human breast cancer cells in vitro. Interactions with high affinity intracellular binding sites and effects on cell proliferation kinetics. Bresciani F, King RJB, Lippman ME, Namer M, Raynaud J-P. Progress in Cancer Research and Therapy. Vol. 31:1984;193-312 Raven Press, New York.
31. Reddel RR, Murphy LC, Sutherland RL. Effects of biologically active metabolites of tamoxifen on the proliferation kinetics of MCF-7 human breast cancer cells in vitro. Cancer Res. 43:1983;4618-4624.
32. Sutherland RL, Watts CKW, Ruenitz PC. Definition of two distinct mechanisms of action of antioestrogens on breast cancer cell proliferation using hydroxytriarylethylenes with high affinity for estrogen receptors. Biochem Biophys Res Commun. 140:1986;523-529.
33. Jordan VC, Clark ER, Allen KE. Structure-activity relationships amongst non-steroidal antioestrogens. Sutherland RL, Jordan VC. Non-steroidal Antiestrogens. 1981;31-57 Academic Press, Sydney.
34. Murphy LC, Sutherland RL. Differential effects of tamoxifen and analogs with nonbasic side chains on cell proliferation in vitro. Endocrinology. 116:1985;1071-1078.
35. Bignon E, Pons M, Crastes dePaulet A, Doré J-C, Gilbert J, Abecassis J, Miquel J-F, Ojasoo T, Raynaud J-P. Effect of triphenylacrylonitrile derivatives on estradiol-receptor binding and on human breast cancer cell growth. J Med Chem. 32:1989;2092-2103.
36. Jones CD, Blaszczak LC, Goettel ME, Suarez T, Crowell TA, Mabry TE, Ruenitz PC, Srivatsan V. Antiestrogens. 3. Estrogen receptor affinities and antiproliferative effects in MCF-7 cells of phenolic analogues of trioxifene, [3,4-dihydro-2-(4-methoxyphenyl)-1-naphthalenyl][4-[2-(1-pyrrolidinyl)ethoxy]-phenyl]methanone. J Med Chem. 35:1992;931-938.
37. Coezy E, Borgen JL, Rochefort H. Tamoxifen and metabolites in MCF-7 cells correlation between binding to estrogen receptor and inhibition of cell growth . Cancer Res. 42:1982;317-323.
38. O'Brian CA, Liskamp RM, Solomon DH, Weinstein IB. Triphenylethylenes a new class of protein kinase C inhibitor . J Natl Cancer Inst. 76:1986;1243-1246.
39. O'Brian CA, Housey GM, Weinstein IB. Specific and direct binding of protein kinase C to an immobilized tamoxifen analogue. Cancer Res. 48:1988;3626-3629.
40. Gulino A, Barrera G, Vacca A, Farina A, Ferretti C, Screpanti I, Dianzani MU, Frati L. Calmodulin antagonism and growth-inhibiting activity of triphenylethylene antiestrogens in MCF-7 human breast cancer cells. Cancer Res. 46:1986;6274-6278.
41. Katzenellenbogen BS, Fang H, Ince BA, Pakdel F, Reese JC, Wooge CH, Wrenn CK. Estrogen receptors ligand discrimination and antiestrogen action . Breast Cancer Res Treat. 27:1993;17-26.
42. Ruenitz PC, Bagley JR, Mokler CM. Estrogenic and antiestrogenic activity of monophenolic analogues of tamoxifen, (Z)-2-[p-(1,2-diphenyl-1-butenyl)phenoxy]-N,N-dimethylethylamine. J Med Chem. 25:1982;1056-1060.
43. Mullick A, Chambon P. Characterization of the estrogen receptor in two antiestrogen-resistant cell lines, LY2 and T47D. Cancer Res. 50:1990;333-338.
44. Robertson DW, Katzenellenbogen JA, Hayes JR, Katzenellenbogen BS. Antiestrogen basicity-activity relationships A comparison of the estrogen receptor binding and antiuterotrophic potencies of several analogues of (Z)-1,2-diphenyl-1-[4-[2-(dimethylamino)ethoxy]phenyl]-1-butene (tamoxifen, Nolvadex) having altered basicity . J Med Chem. 25:1982;167-171.
45. Lednicer D, Lyster SC, Duncan GW. Mammalian antifertility agents. IV. Basic 3,4-dihydronaphthalenes and 1,2,3,4-tetrahydro-1-naphthols. J Med Chem. 10:1967;78-84.
46. Bitonti AJ, Baumann RJ, Bush TL, Cashman EA, Wright CL, Prakash NJ. Antitumor and chemopreventive effects of a clomiphene analog, MDL 103,323, in mammary carcinoma. Anticancer Res. 16:1996;2553-2557.